Jean-Philippe Talarmin

Jean-Philippe Talarmin

Auto-generated profile, based on publicly available information

Jean-Philippe Talarmin

Department of Infectious Diseases, Cornouaille Hospital, Quimper, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2018 in Infectious Diseases
Verified
Journal Article
Closed access
LCLenaïg Le Clech
Lenaïg Le Clech
JTJean-Philippe Talarmin
Jean-Philippe Talarmin
MCMarie-Anne Couturier
Marie-Anne Couturier
JIJean-Christophe Ianotto
Jean-Christophe Ianotto
CNChristophe Nicol
Christophe Nicol
GGGaëlle Guillerm
Gaëlle Guillerm
Introduction: Immediate empirical antibiotic therapy is mandatory in febrile chemotherapy-induced neutropenia, but its optimal duration is unclear, especially in patients with fever of unknown origin (FUO). Objectives: The primary objective of this 20-month prospective observational study was to evaluate the feasibility and safety of short-term antibiotic treatment in afebrile or febrile patients exhibiting FUO, irrespective of their neutrophil count. The secondary objective was to describe the epidemiology of all episodes of febrile neutropenia. Methods: In the first phase of the study, empirical antibiotic therapy in FUO patients was stopped after 48 h of apyrexia, in accordance with European Conference on Infections in Leukaemia guidelines (n = 45). In the second phase of the study, antibiotics were stopped no later than day 5 for all FUO patients, regardless of body temperature or leukocyte count (n = 37). Results: Two hundred and thirty-eight cases of febrile neutropenia in 123 patients were included. Neither the composite endpoint (p = .11), nor each component (in-hospital mortality (p = .80), intensive care unit admission (p = 0.48), relapse of infection ≤48 h after discontinuation of antibiotics (p = .82)) differed between the two FUO groups. Violation of protocol occurred in 17/82 episodes of FUO without any major impact on statistical results. Twenty-six (57.3%) and 22 (59.5%) FUO episodes did not relapse during hospital-stay (p = 1), and nine (20%) and five (13.5%) presented another FUO, respectively. One hundred and fifty-six episodes of febrile neutropenia (65.5%) were clinically or microbiologically documented, including 85 bacteremia. Conclusions: These results suggest that early discontinuation of empirical antibiotics in FUO is safe for afebrile neutropenic patients.

20 January 2023 in Infectious Diseases Now
Verified
Journal Article
Closed access
MLM. Lacasse
M. Lacasse
SDS. Derolez
S. Derolez
EBEric BONNET
Eric BONNET
AAA. Amelot
A. Amelot
BBB. Bouyer
B. Bouyer
VZValerie Zeller
Valerie Zeller

4 August 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AAAlexandra Audemard-Verger
Alexandra Audemard-Verger
AGAmélie Le Gouge
Amélie Le Gouge
VPVincent Pestre
Vincent Pestre
JCJohan Courjon
Johan Courjon
VLVincent Langlois
Vincent Langlois
ACAgnes Caille
Agnes Caille
We aimed to investigate whether anakinra, an interleukin-1receptor inhibitor, could improve outcome in moderate COVID-19 patients. In this controlled, open-label trial, we enrolled adults with COVID-19 requiring oxygen. We randomly assigned patients to receive intravenous anakinra plus optimized standard of care (oSOC) vs. oSOC alone. The primary outcome was treatment success at day 14 defined as patient alive and not requiring mechanical ventilation or extracorporeal membrane oxygenation. Between 27th April and 6th October 2020, we enrolled 71 patients (240 patients planned to been enrolled): 37 were assigned to the anakinra group and 34 to oSOC group. The study ended prematurely by recommendation of the data and safety monitoring board due to safety concerns. On day 14, the proportion of treatment success was significantly lower in the anakinra group 70% (n = 26) vs. 91% (n = 31) in the oSOC group: risk difference—21 percentage points (95% CI, -39 to -2), odds ratio 0.23 (95% CI, 0.06 to 0.91), p = 0.027. After a 28-day follow-up, 9 patients in the anakinra group and 3 in the oSOC group had died. Overall survival at day 28 was 75% (95% CI, 62% to 91%) in the anakinra group versus 91% (95% CI, 82% to 100%) (p = 0.06) in the oSOC group. Serious adverse events occurred in 19 (51%) patients in the anakinra group and 18 (53%) in the oSOC group (p = 0·89). This trial did not show efficacy of anakinra in patients with COVID-19. Furthermore, contrary to our hypothesis, we found that anakinra was inferior to oSOC in patients with moderate COVID-19 pneumonia.

1 October 2021 in Infectious Diseases Now
Verified
Journal Article
Closed access
PMPauline Martinet
Pauline Martinet
LKLydie Khatchatourian
Lydie Khatchatourian
NSNadia Saidani
Nadia Saidani
MFMarie-Sarah Fangous
Marie-Sarah Fangous
DGDorothée Goulon
Dorothée Goulon
JTJean-Philippe Talarmin
Jean-Philippe Talarmin

6 September 2024 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
JTJean-Philippe Talarmin
Jean-Philippe Talarmin
SRSchéhérazade Rezig
Schéhérazade Rezig
LPLucia Grandiere Perez
Lucia Grandiere Perez
MAMathilde Artus
Mathilde Artus
SBSophie Blanchi
Sophie Blanchi
YCYvan Caspar
Yvan Caspar

18 February 2020 in Acta Neurologica Belgica
Verified
Journal Article
Closed access
PDF file
JTJean-Philippe Talarmin
Jean-Philippe Talarmin
SRSchéhérazade Rezig
Schéhérazade Rezig
ATAdissa Tran-Minoui
Adissa Tran-Minoui
CBChristian Berthou
Christian Berthou
JEJean-Richard Eveillard
Jean-Richard Eveillard